Olipass Corporation

Kangwon Jang

Daram Jung

Bongjun Cho

Shin Chung

Hyun Ju Jeon

Soyoung Kim

Jinyoung Bae

Heungsik Yoon

Taeyeon Bae

Yeasel Jeon

Dan Bi An

Jun Yeon Lee

Min Wook Shin

Sun Hwa Park

Provided are peptide nucleic acid derivatives targeting a part of the human HIF-1&#x3b1; pre-mRNA. The peptide nucleic acid derivatives potently induce exon skipping to yield splice variants of HIF-1&#x3b1; mRNA in cells, and are useful to treat indications or conditions involving the overexpression of HIF-1&#x3b1;.

HIF 1-alpha antisense oligonucleotides

Provided are peptide nucleic acid derivatives targeting a 3' splice site of the human SNAP25 pre-mRNA. The peptide nucleic acid derivatives potently induce at least a splice variant of the human SNAP25 mRNA in cells, and are useful to safely treat dermatological indications or conditions involving the expression of the human SNAP25 protein by topical administration.

SNAP25 antisense oligonucleotides

The current invention provides peptide nucleic acid derivatives targeting the 3' splice site of exon 4 in the human SCN9A pre-mRNA. The peptide nucleic acid derivatives potently induce SCN9A mRNA splice variant(s) lacking the SCN9A exon 4 in cells, and are useful to safely treat pains or conditions involving Na1.7 activity.

SCN9A antisense pain killer

Growing community of inventors

Yongin-si, South Korea

Kangwon Jang